Co ongestive heart failure is a common cause of early death from large myocardial infarctions. The likelihood of the development of pump failure and cardiogenic shock increases with the size of infarction. In an autopsy study by Page et al,1 all the patients who died of shock had an infarct involving more than 40% of the left ventricle. Other autopsy studies showing the high incidence of shock with large myocardial infarctions provided further evidence that a critical amount of uninfarcted myocardium is necessary to allow survival.2-5 Studies in dogs indicated that no more than 30% to 35% of the left ventricle could be removed without causing heart failure and death.67 From these data, there emerged a consensus that a patient probably would not survive a myocardial infarction involving more than 40% of the left ventricle.8 Limitations in the methods of assessing infarct size in vivo in humans have previously precluded any accurate assessment. Recently, a method using 9'Tc Sestamibi imaging has been developed for in vivo measurement of infarct size. [9] [10] [11] [12] [13] [14] [15] [16] Using this technique in a prospective study, 16 survivors of large, acute myocardial infarction involving greater than 40% of the left ventricle are described with a surprisingly good prognosis during follow-up for a mean of 13 months.
Methods

Study Group
A consecutive series of patients was enrolled in a series of prospective studies of the utility of 9'Tc Sestamibi in acute myocardial infarction. Inclusion criteria were as follows: (1) 
Radionuclide Perfusion Studies
Tomographic radionuclide acquisitions were performed at discharge (median, 7 days after infarction), 1 to 6 hours after injection of 20 to 30 mCi of 9'Tc Sestamibi using previously described techniques (Figure) .9.12'13 Quantitation of the extent of left ventricular infarction was performed using five representative short-axis slices and a threshold technique as previously reported.9 Technetium-99m Sestamibi measurements of infarct size have been validated in animal models of permanent occlusion16 and reperfusion. 11, 17 Radionuclide Angiography Equilibrium radionuclide angiography was performed at hospital discharge (1 day after 99mTc Sestamibi imaging), at 6 weeks, and at 1 year when possible. Ejection fraction was measured using previously described techniques. 18 Clinical Follow-up
The patients were followed for early (in the first 24 hours) and late (24 hours after admission to discharge) in-hospital complications of infarction. All the patients have been seen as outpatients in follow-up since discharge.
Results
Sixteen patients were identified and followed who at hospital discharge had final infarct sizes greater than 40% despite acute reperfusion therapy ( Studies using serum creatine phosphokinase (CPK) to size myocardial infarction in vivo have shown that nonsurvivors and patients with shock tend to have larger infarctions than survivors and patients without shock. Sobel et a123 showed that mortality was significantly increased in patients with more than 65 g of infarcted myocardium estimated by total serum CPK release, although two thirds of this group survived with class III to IV heart failure.23 In the study by Bleifeld et al,24 six patients had infarct sizes greater than 100 g of myocardium (three had infarct sizes determined at autopsy). Two of these six patients with very large infarctions survived without shock. As a result, in an individual patient, infarct size was not specific in predicting mortality or shock; the mass and function of the residual, noninfarcted myocardium were more important.
In the Western Washington Intracoronary Streptokinase Trial, Ritchie et a125 used`"Tl tomography to assess infarct size in vivo 6 weeks after infarction in 100 patients. The range of infarct sizes was not presented for this population of infarct survivors, but streptokinase-treated anterior infarcts (n=24) were reported to be 27.8±12.2% of the left ventricle. With this standard deviation, it is probable that some of these infarct survivors had infarct sizes greater than 40%, particularly as the imaging technique used in their study underestimates anatomic infarct size. 26 Selection bias in our study will 
